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Abstract
Background Limited information has been published regarding how specific processes for event
adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported
by site investigators in the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and those adjudicated by a central
clinical events committee (CEC) to determine the reasons for differences in event rates. 
Methods The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive
eptifibatide or placebo. The primary end-point was death or post-enrolment MI at 30 days as assessed
by the CEC; this end-point was also constructed using site-reported events. The CEC identified
suspected MIs by systematic review of clinical, cardiac enzyme, and electrocardiographic data.
Results The CEC identified 5005 (46%) suspected events, of which 1415 (28%) were adjudicated as
MI. The site investigator and CEC assessments of whether a MI had occurred disagreed in 983 (20%)
of the 5005 patients with suspected MI, mostly reflecting site misclassification of post-enrolment MIs (as
enrolment MIs) or underreported periprocedural MIs. Patients for whom the CEC and site investigator
agreed that no end-point MI had occurred had the lowest mortality at 30 days and between 30 days and
6 months, and those with agreement that a MI had occurred had the highest mortality.
Conclusion CEC adjudication provides a standard, systematic, independent, and unbiased assessment
of end-points, particularly for trials that span geographic regions and clinical practice settings.
Understanding the review process and reasons for disagreement between CEC and site investigator
assessments of MI is important to design future trials and interpret event rates between trials.
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Introduction
MI is a potentially catastrophic event in patients presenting
with acute coronary syndromes. In recent trials of
antiplatelet and antithrombotic therapies for such patients,
prevention of MI was the primary treatment effect assessed
[1–4]. Although MI has been considered a ‘hard’ end-point,
determination of MI end-points in clinical trials can be diffi-
cult, just as in clinical practice. Because of conflicting clini-
cal, laboratory, and electrocardiography (ECG) data,
physicians often disagree whether a patient has suffered a
MI. The importance of low-level enzyme elevations also has
been controversial, particularly in asymptomatic patients
and in those undergoing percutaneous coronary interven-
tion (PCI) [5]. Although such enzyme elevations are
defined as MIs in many trial protocols, physicians in clinical
practice do not consistently consider them as such. The MI
rates reported by site investigators in recent cardiovascular
trials have differed from rates adjudicated by a CEC [6–9].
The reasons for these differences are unclear.
CECs are widely accepted to adjudicate suspected end-
point events in trials, but only limited information has been
published regarding end-point adjudication [10–15]. In
the PURSUIT trial [6], a central, independent CEC sys-
tematically identified and adjudicated all suspected MIs
that occurred up to 30 days after enrolment. The rationale
for CEC adjudication was the need for a systematic, unbi-
ased, independent, and standard assessment of MIs in a
large international trial. In a previous analysis of the CEC
process in the PURSUIT trial, we found that the CEC and
site investigator assessments of end-point MI disagreed in
~10% of patients [16]. We retrospectively reviewed these
cases, to identify reasons for them and to understand their
potential effect on the trial results.
Materials and methods
The PURSUIT trial
The PURSUIT trial examined the role of eptifibatide, a
platelet glycoprotein IIb/IIIa antagonist, in patients present-
ing with acute coronary syndromes without persistent ST-
segment elevation. The trial enrolled 10,948 patients in
726 hospitals in 27 countries in North America, Latin
America, Western Europe, and Eastern Europe, using pre-
viously reported inclusion and exclusion criteria and treat-
ment regimens [6]. The primary end-point was a
composite of death or post-enrolment MI (or reinfarction if
patients had a MI at enrolment) by 30 days as adjudicated
by a CEC. The composite end-point was also constructed
using the site investigator determination of MI.
Definitions
The protocol defined MI as an end-point event based on
clinical, ECG, and laboratory criteria (see Appendix); MIs
that occurred before or at enrolment were not included in
the primary end-point. The site investigators and the CEC
used the same MI criteria. These criteria were presented in
the protocol, at investigator meetings, and in trial materials
and newsletters.
Data collection
Data were captured on standard case report forms. Infor-
mation collected for all patients included cardiac enzymes,
ECGs (at the time of the qualifying episode, at enrolment,
at 24 hours, at initial discharge, and at 30 days), revascu-
larisation procedure reports, details of ischemic episodes,
clinical complications, medications, and readmission
records. All enzyme values for each patient were to be
reported, and study monitors verified them against source
documents. For patients with suspected MI, site investiga-
tors were to submit supporting documents and to include
discharge summaries and additional ECGs during the sus-
pected event. An independent, blinded, ECG Core Labo-
ratory read the ECGs and identified suspected MIs,
defined as new Q waves ≥0.04 s in two contiguous leads. 
Clinical events classification process
The structure of the CEC and the event adjudication
process have been reported in detail elsewhere [16]. Com-
puter algorithms systematically identified key clinical, enzy-
matic, and ECG data from the database that could indicate
the occurrence of a MI. Each case of suspected MI was
reviewed independently by two physicians blinded to treat-
ment. If the physicians agreed that a MI had or had not
occurred, the case was classified as resolved. A committee
of faculty cardiologists reviewed patients about which the
CEC physicians disagreed, for adjudication by consensus.
Disagreements between the site investigators and CEC
A faculty cardiologist (KWM, RAH, BSC) re-reviewed
patients with disagreement between the site investigator
assessment and the CEC adjudication of end-point MI, to
determine reasons for the disagreement. This review
occurred after the main trial results were presented, but
the reviewers were blinded to patient treatment assign-
ment. Patients were categorised during the re-review in
clinically meaningful groups: MI at enrolment (versus post-
enrolment MI), MI related to the revascularisation proce-
dure, MI related to clinically evident ischemia,
asymptomatic cardiac enzyme elevation post-enrolment,
and clinically significant cardiac event resulting in death
(versus sudden death without evidence of MI).
Despite rigorous criteria to define MI, some patients
required a subjective assessment by CEC physicians if
cardiac enzyme, ECG, and clinical information conflicted.
For patients with MI identified by the CEC but not by the
site investigator (excluding events after PCI or bypass
surgery), we therefore assigned a level of clinical certainty.
A high clinical certainty was assigned when all clinicians
agreed that a MI had occurred; a low clinical certainty was
assigned when only some clinicians would agree that a MI
had occurred.
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Statistical analysis
Data regarding the number of patients with suspected
events and those with disagreements between the site
investigators and the CEC were obtained from the entire
PURSUIT study population, so the data included patients
assigned high-dose eptifibatide, low-dose eptifibatide, or
placebo. Comparisons by treatment assignments included
only patients assigned to high-dose eptifibatide or
placebo to maintain consistency with the primary efficacy
analysis in the PURSUIT trial [6]. P values were calculated
using the χ2 test.
Results
Incidence of disagreement
Overall, 5005 (46%) patients with possible or suspected MI
were identified and adjudicated by the CEC. The CEC iden-
tified more patients with end-point events than did the site
investigators (13.6% versus 7.7% for placebo, 12.6%
versus 6.2% for eptifibatide). The CEC and site investigator
assessments of MI disagreed for 9% of all patients enrolled
in the PURSUIT trial. The CEC identified MIs in 1415 of the
5005 patients with suspected MI. The site investigator and
the CEC assessments disagreed in 983 (20%) of the 5005
patients. Of these 983 patients with disagreements, 816
patients had a MI identified by the CEC but not the site
investigator, and 167 patients had a MI identified by site
investigator but not the CEC. The proportion of patients
with disagreement was similar among regions.
Reasons for disagreement
Most often, when the site investigator had identified a MI
and the CEC had not, the investigator had misclassified a
MI at enrolment as an end-point MI, although by protocol
these were not end-point events (Table 1). Recurrent
ischemic events without elevated cardiac enzymes or
ECG evidence of MI were also incorrectly identified by
site investigators as MIs (Table 1). In cases where the
CEC had identified a MI and the site investigators had not,
one-third of those identified were MIs defined by enzyme
elevations without clinical or ECG evidence of ischemia or
infarction (Table 2). Enzyme elevations after bypass
surgery accounted for 25% of these cases. Patients with
clinically evident ischemia reported by the site investigator
and associated with cardiac enzyme elevations were not
reported as MIs by investigators in 27% of the cases of
disagreement (Table 2). Few infarctions based on new Q
waves without clinical evidence of reinfarction were identi-
fied by the CEC and not by site investigators.
Table 3 presents the cardiac enzyme elevation for MIs that
the CEC identified and the site investigators did not.
These data exclude MIs associated with PCI or bypass
surgery; by definition, those types of MI required enzyme
elevations greater than three or five times the upper limit of
normal (ULN), respectively. The ratio of creatine kinase-
myocardial band (CK-MB) to its ULN was highest in North
America (median [25th, 75th] 1.6 [1.2, 2.9]). Enzymes were
similarly elevated between patients with MIs defined only
by enzyme elevations (without symptoms or ECG
changes) and patients with elevations associated with
ECG or clinical evidence of ischemia.
Table 4 presents the level of clinical certainty for MIs not
associated with PCI or bypass surgery, as identified by the
CEC but not the site investigators. Overall, 98 (18%) of
these patients were assigned a low level of clinical cer-
tainty. The proportion of patients assigned a low level of
clinical certainty varied among the regions, with the lowest
in North America.
Effect of disagreement on outcomes
The 30-day CEC rates of MI and death or MI overall are
presented in Table 5 by geographic region. The event
rates are also shown for the analyses in which the 98
patients assigned a low level of certainty were reclassified
as no infarction.
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Table 1
Myocardial infarctions identified by site investigators but not confirmed by the clinical events committee
Eastern Europe Latin America North America Western Europe Overall 
Clinical scenario (n = 24) (n = 8) (n = 57) (n = 78) (n = 167)
Enrolment myocardial infarction* 8 (33) 4 (50) 24 (42) 28 (36) 64 (38)
Ischemic event without infarction† 7 (29) 0 (0) 8 (14) 19 (24) 34 (20)
Peri-death infarction‡ 6 (25) 2 (25) 13 (23) 8 (10) 29 (17)
Percutaneous coronary intervention related 0 (0) 1 (12.5) 6 (11) 10 (13) 17 (10)
Coronary artery bypass surgery related 2 (8) 1 (12.5) 5 (9) 7 (9) 15 (9)
Miscellaneous 1 (4) 0 (0) 1 (2) 6 (8) 8 (5)
Data presented as n (%). * Not an end-point event per protocol. † Clinical evidence of ischemia without electrocardiography (ECG) or cardiac
enzyme evidence of infarction. ‡ Infarction suspected at the time of death without supporting clinical, ECG, or cardiac enzyme data.
The lowest mortality rates were in patients for whom the
CEC and site investigators agreed that no MI had occurred
by 30 days (Table 6). The highest rates were in patients for
whom there was agreement that a MI had occurred. Mortal-
ity was high in the group with MI identified by the site inves-
tigators but not the CEC; however, many of these patients
had suspected sudden cardiac death as the event identi-
fied as a MI by the investigator (Table 1). The absolute
increase in mortality between 30 days and 6 months was
greater in patients with CEC-determined MIs not identified
by the site investigators than in patients with MI identified
by the site investigators but not the CEC.
Discussion
This analysis of the adjudication process of nonfatal MI by
a central CEC in the PURSUIT trial has five key findings.
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Table 3
Enzyme elevations in patients with myocardial infarction identified by the clinical events committee but not the site investigator*
Median peak CK/ULN Median peak CK-MB/ULN 
Region n (25th, 75th percentiles) n (25th, 75th percentiles)
Eastern Europe 172 0.6 (0.3, 1.2) 167 1.4 (1.2, 1.9)
Latin America 34 0.7 (0.4, 1.2) 34 2.0 (1.3, 2.6)
North America 112 1.6 (1.0, 3.1) 106 2.9 (1.5, 5.5)
Western Europe 202 0.7 (0.4, 2.0) 196 1.7 (1.2, 3.0)
Overall 520 0.9 (0.4, 1.9) 503 1.6 (1.2, 2.9)
Table 4
Level of clinical certainty* for myocardial infarction identified by the clinical events committee but not the site investigator
High certainty Low certainty Total
Eastern Europe 133 (76) 42 (24) 175
Latin America 21 (58) 15 (42) 36
North America 111 (98) 2 (2) 113
Western Europe 177 (82) 39 (18) 216
Overall 442 (82) 98 (18) 540
Data presented as n (%). * See Methods.
Table 2
Myocardial infarctions identified by the clinical events committee but not the site investigator
Eastern Europe Latin America North America Western Europe Overall 
Clinical scenario (n = 182) (n = 44) (n = 299) (n = 291) (n = 816)
Asymptomatic CK-MB elevation* 83 (46) 23 (52) 37 (12) 128 (44) 271 (33)
Ischemic event† 89 (49) 12 (27) 48 (16) 68 (23) 217 (27)
Coronary artery bypass graft-related 6 (3) 6 (14) 138 (46) 52 (18) 202 (25)
PCI-related 2 (1) 1 (2) 62 (21) 22 (8) 87 (11)
Early myocardial infarction‡ 1 (1) 0 (0.0) 3 (1) 3 (1) 7 (1)
Isolated electrocardiogram (Q waves)§ 1 (1) 1 (2) 5 (2) 4 (1) 11 (1)
Peri-death¶ 0 (0) 1 (2) 1 (0.3) 4 (1) 6 (1)
Miscellaneous 0 (0) 0 (0) 5 (2) 10 (3) 15 (2)
Data presented as n (%). CK-MB, CK-MB = creatine kinase-myocardial band; PCI, percutaneous coronary intervention. * No clinical symptoms or
electrocardiography (ECG) evidence of ischemia. † Clinical evidence of ischemia and ECG/cardiac enzyme evidence of infarction. ‡ Cardiac
enzyme or ECG evidence of infarction < 24 hours after enrolment, different from the enrolment event. § Identified by systematic review of ECGs
without clinical evidence of reinfarction. ¶ Myocardial infarction at the time of death with clinical, ECG, or cardiac enzyme evidence.
First, post-enrolment MI rates were higher than those
reported in prior trials of acute coronary syndromes.
Second, the site investigator and CEC assessments of
end-point MI disagreed for nearly 10% of all patients
enrolled. Third, the site investigators underreported proto-
col-defined end-point MIs. Fourth, the observed treatment
effect was smaller using the CEC-adjudicated MI rates
versus site investigator-identified event rates. Finally, in a
retrospective analysis that excluded patients with post-
enrolment MI who had conflicting clinical, ECG, and
cardiac enzyme data (although they met prespecified end-
point criteria), the treatment effect was larger than that
seen when such patients were included. These findings, in
aggregate, suggest the use of a CEC is important for sys-
tematic ascertainment of nonfatal end-points. The defini-
tion of MI and its application in CEC event adjudication in
the PURSUIT trial may, however, have been too inclusive
of MIs defined by low-level enzyme elevations, which
either represented ‘noise’ or clinically unimportant events.
Event rates
The MI rates adjudicated by the CEC in the PURSUIT trial
were higher than those reported in trials of similar patient
populations [6,17–19]. The reasons for these higher rates
have been detailed previously [16], and include the review
of nearly 50% of patients by physicians to identify
suspected events, more liberal MI criteria, and rigorous
measurement of cardiac enzymes in all patients. Studies
that have used only investigator-reported events probably
underestimate the true MI rate.
Lack of concordance between site investigator and CEC
event rates
Site investigators underreported MIs. A similar lack of con-
cordance between events adjudicated by a CEC and
those identified by clinical investigators has been
observed in trials in which a similar CEC group adjudi-
cated MIs [1,8] and in other trials [7,9].
The MI definitions in the PURSUIT trial were formulated by
the International Steering Committee based on experience
and clinical expertise. Because of the broad geographic
enrolment planned for the PURSUIT trial, definitions were
designed to be applicable in an array of clinical practice
situations. The definitions were detailed in the study proto-
col, in study newsletters, and in study materials so the
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Table 5
Clinical events committee event rates (%) at 30 days
All patients With reclassification*
Event Eptifibatide Placebo P Eptifibatide Placebo P
Death or myocardial infarction
Eastern Europe 21.0 19.7 18.0 17.9
Latin America 16.1 15.7 14.1 13.2
North America 11.7 15.0 11.7 15.0
Western Europe 13.8 14.8 12.9 13.7
Overall 14.2 15.7 0.042 13.3 14.9 0.021
Myocardial infarction
Eastern Europe 18.8 17.3 15.8 15.3
Latin America 11.6 11.7 9.6 9.1
North America 10.1 12.9 10.1 12.9
Western Europe 12.6 12.9 11.7 11.8
Overall 12.6 13.6 0.137 11.6 12.7 0.08
*See Methods; 98 patients with low clinical certainty reclassified as having no infarction.
Table 6
Mortality (30 days and 6 months) for cases of disagreement
Mortality (%)
n 30 days 30 days–6 months 6 months
CEC no / site no 9366 1.7 2.1 3.8
CEC yes / site yes 599 22.0 5.7 27.7
CEC yes / site no 816 7.2 5.4 12.6
CEC no / site yes 167 24.0 2.3 26.3
CEC, Clinical events committee.
CEC and site investigators had the same set of criteria to
classify MIs.
The reasons for disagreements in MI assessment between
the site investigators and the CEC in the PURSUIT trial
(Tables 1 and 2) are similar to those seen in the Global Use
of Strategies to Open Occluded Arteries in Acute Coronary
Syndromes (GUSTO-IIb) and the Integrilin to Minimize
Platelet Aggregation and Coronary Thrombosis (IMPACT-II)
trials (unpublished personal data). Many of the disagree-
ments reflect physician reluctance to diagnose MI in
patients they are treating, particularly when the definition of
MI includes events with low-level cardiac enzyme elevations
(often called ‘enzyme leaks’ in clinical practice). This reluc-
tance by physicians to diagnose MI is also apparent for
patients undergoing PCI, in which the clinical significance of
postprocedural enzyme elevations is controversial, even
though such elevations correlate with worse outcome [5].
The disagreements also may partly reflect the definitions
(see Appendix) of MI themselves. These definitions were
designed to be applied to a broad set of clinical scenarios,
including events after PCI or bypass surgery, and to
events occurring early after enrolment, which needed to
be differentiated from pre-enrolment or enrolment MIs.
Site investigators may have had difficulty applying these
criteria, particularly with conflicting cardiac enzyme, ECG,
and clinical information. In addition, the enzyme criteria in
the PURSUIT trial required only one cardiac enzyme value
above normal to provide supportive evidence of MI. Sub-
stantial clinical uncertainty exists regarding the need for
more than one elevated enzyme value and whether the
CK-MB criteria should specify elevations greater than
1 × ULN or 2 × ULN.
The strategy used by a CEC to adjudicate MIs can
dramatically influence event rates and the proportion of
events with disagreements between site investigators and
a CEC. Some trials have confirmed only events reported by
the investigators [9,17–21], while other trials have adjudi-
cated all suspected events identified by systematic screen-
ing of patient data [1–3,7,8,22]. When only events
reported by investigators are reviewed by a CEC, the
reported event rates will be identical to or lower than the
site investigator rates. When events are identified indepen-
dently by the CEC, the CEC event rates may be higher,
lower, or the same as the site investigator-reported rates.
Difference in treatment effect
The absolute difference in the MI rates was 1.6% (6.2%
for eptifibatide versus 7.8% for placebo) as assessed by
the site investigators, and 1.0% (12.6% versus 13.6%) as
adjudicated by the CEC. The higher event rates in both
treatment arms using the CEC data, despite the similar
absolute difference, reduced the relative treatment effect
(7.4% versus 20.5% reduction) as expected. A similar
decrease in relative treatment effect has been noted in
some trials [1,8] but not others [17–19].
The MIs determined by cardiac enzyme elevations without
clinical symptoms or ECG changes accounted for 33% of
the disagreements in which the CEC identified a MI and
the site investigators did not. The median CK-MB eleva-
tion in these events was 1.6 × ULN. About 50% of these
events were thus defined by CK-MB values between
1 × ULN and 1.5 × ULN, with normal median CK values
(0.9 × ULN) (Table 3).
A retrospective but blinded review of MIs identified by the
CEC but not the site investigator found that 18%
(98/540) of these patients were assigned a low level of
clinical certainty. This was because, although the CK or
CK-MB elevations met the end-point criteria, the cardiac
enzyme data were considered inconsistent or unreliable,
or were associated with conflicting clinical and ECG data.
We noted regional differences in the proportion of
patients with low clinical certainty. The highest proportions
were in Eastern Europe and Latin America, where the
observed treatment effect using the CEC definition was
negligible. Furthermore, the magnitude of the enzyme ele-
vations (Table 3) parallels discrepancies in the assigned
level of certainty. The highest enzyme elevations were
observed in North America (median CK-MB elevation,
2.9 × ULN; median CK elevation, 1.6 × ULN), where the
treatment effect was most pronounced. CK-MB elevations
in other regions were less striking (median CK-MB eleva-
tion, 1.4 × ULN–2.0 × ULN). The regional differences in
treatment effect are, however, complex and include differ-
ences in patient demographics, the use of cardiac proce-
dures, medications and revascularisation, and the
reliability of laboratory data [23]. These findings support
the hypothesis that including MI end-points defined by
low-level cardiac enzyme elevations or events associated
with conflicting clinical and ECG data may dilute the
actual treatment effect.
Predictive value of CEC-identified events
The 30-day treatment effect was reduced using CEC-
adjudicated end-points versus site investigator assess-
ments, but patients with events adjudicated by the CEC
(but not identified by the site investigators) had greater
mortality between 30 days and 6 months than did patients
with MI reported only by the site investigators (Table 6). In
addition, MIs identified by a similar CEC process have
been associated with worse long-term outcomes at 3-year
follow-up [24]. These data suggest that events identified
by the CEC alone are of prognostic importance.
Implications
CEC adjudication of suspected nonfatal MI end-point
events is important to provide independent, unbiased,
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standard, systematic assessment. The CEC adjudication
does have certain limitations. The criteria used to define
MI must be evaluated. The determination of MI may require
more clinical judgment in patients with inconsistent clinical
history, cardiac enzyme data, and ECG information, or
suspect cardiac enzyme data. We recognise that this may
decrease the objectivity that is important for event classifi-
cation, particularly in trials across geographic regions and
clinical practice settings. At a minimum, events charac-
terised by a low level of clinical certainty should not be
classified as MIs.
Although the absolute difference in infarction rates deter-
mined by the CEC versus site investigators was small, the
relative difference was more substantial. This caused a
substantial impact on the statistical outcome of the trial.
This phenomenon must be considered in calculations of
sample size and power during design of future trials, and
also may influence how clinical and regulatory bodies
interpret trial results. In addition, the CEC process used
must be considered, among other factors, when perform-
ing comparisons of event rates between trials.
Conclusions
Nonfatal MI is an important clinical outcome, and its pre-
vention is a key measure of efficacy in evaluating new ther-
apies for acute coronary syndromes. The determination of
MI can be difficult in clinical practice due to conflicting
clinical, cardiac enzyme, and ECG data. The CEC adjudi-
cation of MI provides a standard, systematic, independent,
and unbiased assessment of this end-point in clinical
investigations. In the PURSUIT trial, the assessments of MI
by site investigators and a central CEC disagreed; more
MIs were identified by the CEC than by site investigators.
Most disagreements reflected underreporting of proce-
dure-related events and misclassification of enrolment MIs
as post-enrolment (end-point) MIs. Understanding the
CEC process used in a trial is important in interpreting
event rates, particularly when comparing rates between
trials. The type of CEC process also has implications in
calculations of sample size and power. Our review of the
PURSUIT trial CEC experience has highlighted some of
these important issues and the need to further evaluate
the strategies used for event adjudication.
Competing interests
None declared.
Acknowledgements
The PURSUIT study was funded by grants from COR Therapeutics,
Inc. (South San Francisco, CA, USA) and Schering-Plough Corpora-
tion (Madison, NJ, USA).
References
1. The GUSTO-IIb Investigators: A comparison of recombinant
hirudin with heparin for the treatment of acute coronary syn-
dromes. N Engl J Med 1996, 335:775-782.
2. The EPIC Investigators: Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk
coronary angioplasty. N Engl J Med 1994, 330:956-961.
3. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous coronary
revascularization. N Engl J Med 1997, 336:1689-1696.
4. The Antiplatelet Trialists’ Collaboration: Collaborative overview
of randomised trials of antiplatelet therapy I: prevention of
death, myocardial infarction, and stroke by prolonged
antiplatelet therapy in various categories of patients. Br Med J
1994, 308:81-106.
5. Califf RM, Abdelmeguid AE, Kuntz R, Popma JJ, Davidson CJ,
Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ,
Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS,
Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM:
Myonecrosis after revascularization procedures. J Am Coll
Cardiol 1998, 31:241-251. 
6. The PURSUIT Investigators: Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary syn-
dromes without persistent ST-segment elevation: a random-
ized, placebo-controlled, clinical trial. N Engl J Med 1998,
339:436-443.
7. The CAVEAT Study Group: A comparison of directional
atherectomy with coronary angioplasty in patients with coro-
nary artery disease. N Engl J Med 1993, 329:221-227.
8. The IMPACT-II Investigators: Randomised placebo-controlled trial
of effect of eptifibatide on complications of percutaneous coro-
nary intervention — IMPACT-II. Lancet 1997, 349:1422-1428.
9. The SAVE Investigators: Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after
myocardial infarction: results of the Survival and Ventricular
Enlargement Trial. N Engl J Med 1992, 327:669-677.
10. Walter SD, Cook DJ, Guyatt GH, King D, Troyan S, for the Cana-
dian Lung Oncology Group: Outcome assessment for clinical
trials: how many adjudicators do we need? Contr Clin Trials
1997, 18:27-42.
11. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley
PM, Cruise RG, Theroux S: Surveillance and ascertainment of
cardiovascular events. The Cardiovascular Health Study. Ann
Epidemiol 1995, 5:278-285.
12. Remington RD: Who should code cause of death in a clinical
trial? Contr Clin Trials 1984, 5:241-244.
13. Moussa MA, Shafie MZ, Khogali MM, el-Sayed AM, Sugathan TN,
Cherian G, Abdel-Khalik AZ, Garada MT, Verma D: Reliability of
death certificate diagnoses. J Clin Epidemiol 1990, 43:1285-1295.
14. Early Treatment Diabetic Retinopathy Study Research Group:
Grading diabetic retinopathy from stereoscopic color fundus
photographs — an extension of the modified Airlie House
classification. ETDRS report number 10. Early Treatment Dia-
betic Retinopathy Study Research Group. Ophthalmology
1991, 98(suppl):786-806.
15. Graafsma YP, Prins MH, Lensing AW, de Haan RJ, Huisman MV,
Buller HR: Bleeding classification in clinical trials: observer
variability and clinical relevance. Thromb Haemost 1997, 78:
1189-1192.
16. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan
LG, Tardiff BE, Granger CG, Crenshaw BS, DeJong I, Bhapkar M,
Lee KL, Deckers J, Simoons ML, Topol EJ, Califf RM, for the
PURSUIT Investigators: Systematic adjudication of myocardial
infarction end-points in an international clinical trial. Curr
Contr Trials Cardiovasc Med 2001, 2:180–186.
17. Thrombolysis in Myocardial Ischemia (TIMI) Study Group: Effects
of tissue plasminogen activator and a comparison of early
invasive and conservative strategies in unstable angina and
non-Q-wave myocardial infarction. Results of the TIMI IIIB
trial. Circulation 1994, 89:1545-1556.
18. The PRISM PLUS Investigators: Inhibition of the platelet glyco-
protein IIb/IIIa receptor with tirofiban in unstable angina and
non-Q-wave myocardial infarction. N Engl J Med 1998, 338:
1488-1497.
19. The PRISM Investigators: A comparison of aspirin plus tirofiban
with aspirin plus heparin for unstable angina. N Engl J Med
1998, 338:1498-1505.
20. The CAPTURE Investigators: Randomised placebo-controlled
trial of abciximab before and during coronary intervention in
refractory unstable angina — the CAPTURE study. Lancet
1997, 349:1429-1435.
Available online http://cvm.controlled-trials.com/content/2/4/187
com
m
entary
review
research
21. Antman EM, for the TIMI 9B Investigators: Hirudin in acute
myocardial infarction. Thrombolysis and Thrombin Inhibition
in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94:
911-922.
22. The RESTORE Study Group: Effects of platelet glycoprotein
IIb/IIIa blockade with tirofiban on adverse cardiac events in
patients with unstable angina or acute myocardial infarction
undergoing coronary angioplasty. Circulation 1997, 96:1445-
1453.
23. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska
J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf
RM, Simoons ML, for the PURSUIT Investigators: Geographic
variability in outcomes within an international trial of glyco-
protein IIb/IIIa inhibition in patients with acute coronary syn-
dromes: results from PURSUIT. Eur Heart J 2000, 21:371-381.
24. The EPIC Investigator Group: Long-term protection from
myocardial ischemic events in a randomized trial of brief inte-
grin β3 blockade with percutaneous coronary intervention.
JAMA 1997, 278:479-484.
Appendix: definition for post-enrolment
myocardial infarction
Enzyme criteria
1. Myocardial infarction (events without documentation of
previous infarction during the admission): creatine
kinase-myocardial band (CK-MB) level above the
upper limit of normal (ULN) and ≥3% of total CK. If
CK-MB was unavailable, then total CK > 2 × ULN.
2. Myocardial reinfarction (events with documentation of
an infarction before or at enrolment):
If <18 hours since previous infarction. Recurrent,
severe ischemic discomfort and new, recurrent ST-
segment elevation ≥0.1 mV in at least two contiguous
leads, either persisting ≥30 min.
If ≥18 hours since previous infarction. Re-elevation of
CK-MB to above the ULN (if prior CK-MB was within
normal range) or >50% above the prior level (if prior CK-
MB was above normal). If CK-MB was unavailable: either
total CK ≥2 × ULN and increased by ≥25%; or
≥1.5 × ULN and increased by ≥200 IU above prior value.
3. Periprocedural infarction (events occurring during or
within 24 hours of percutaneous coronary interven-
tion): CK-MB level ≥3 × ULN and > 50% above prior
nadir value. If CK-MB was unavailable, total CK
≥3 × ULN.
4. Perioperative infarction (events occurring during or
within 36 hours of bypass surgery): CK-MB ≥5 × ULN
(or CK, in the absence of CK-MB).
ECG criteria
New, significant Q waves or equivalents ≥0.04 s in at
least two contiguous leads. When enzyme or electrocar-
diographic (ECG) data were unavailable, an infarction was
identified when the bulk of clinical evidence (patient signs,
symptoms, ECG changes, and pathological findings) so
indicated.
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